CDMOs/CMOs: The Key Moves in 2026
What have been key moves—capacity additions and acquisitions by CDMOs of drug substances (small molecules and biologics) thus far in 2026? A roundup of key developments.
PolyPeptide
Samsung Biologics Launches CHF 1.46 Billion Tender Offer for PolyPeptide
Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.
Samsung Biologics to Acquire PolyPeptide in All-Cash Deal, Expanding Global Manufacturing
PolyPeptide's specialized peptide expertise and global multi-site network to strengthen Samsung Biologics' multi-modality and global manufacturing excellence.
PolyPeptide Group Appoints Raymond De Vré as new CEO
PolyPeptide Group has appointed Raymond De Vré as its new Chief Executive Officer (CEO). He will succeed Jane Salik who, after 15 years in this position, will concentrate on her role on the Board of Directors.
